Injection of nanoparticle has proven effective in mouse models, researchers say
Researchers at Tel Aviv University have developed a novel nano-vaccine for melanoma, the most aggressive type of skin cancer. Their innovative approach has so far proven effective in preventing the development of melanoma in mouse models and in treating primary tumors and metastases that result from melanoma.
The focus of the research is on a nanoparticle that serves as the basis for the new vaccine. The study was led by Prof. Ronit Satchi-Fainaro, chair of the Department of Physiology and Pharmacology and head of the Laboratory for Cancer Research and Nanomedicine at TAU’s Sackler Faculty of Medicine, and Prof. Helena Florindo of the University of Lisbon while on sabbatical at the Satchi-Fainaro lab at TAU; it was conducted by Dr. Anna Scomparin of Prof. Satchi-Fainaro’s TAU lab and postdoctoral fellow Dr. João Conniot. The results were published on August 5 in Nature Nanotechnology.
Melanoma develops in the skin cells that produce melanin or skin pigment. “The war against cancer in general, and melanoma in particular, has advanced over the years through a variety of treatment modalities, such as chemotherapy, radiation therapy and immunotherapy; but the vaccine approach, which has proven so effective against various viral diseases, has not materialized yet against cancer,” says Prof. Satchi-Fainaro. “In our study, we have shown for the first time that it is possible to produce an effective nano-vaccine against melanoma and to sensitize the immune system to immunotherapies.”
The researchers harnessed tiny particles, about 170 nanometers in size, made of a biodegradable polymer. Within each particle, they “packed” two peptides — short chains of amino acids, which are expressed in melanoma cells. They then injected the nanoparticles (or “nano-vaccines”) into a mouse model bearing melanoma.
“The nanoparticles acted just like known vaccines for viral-borne diseases,” Prof. Satchi-Fainaro explains. “They stimulated the immune system of the mice, and the immune cells learned to identify and attack cells containing the two peptides — that is, the melanoma cells. This meant that, from now on, the immune system of the immunized mice will attack melanoma cells if and when they appear in the body.”
The researchers then examined the effectiveness of the vaccine under three different conditions.
First, the vaccine proved to have prophylactic effects. The vaccine was injected into healthy mice, and an injection of melanoma cells followed. “The result was that the mice did not get sick, meaning that the vaccine prevented the disease,” says Prof. Satchi-Fainaro.
Second, the nanoparticle was used to treat a primary tumor: A combination of the innovative vaccine and immunotherapy treatments was tested on melanoma model mice. The synergistic treatment significantly delayed the progression of the disease and greatly extended the lives of all treated mice.
Finally, the researchers validated their approach on tissues taken from patients with melanoma brain metastases. This suggested that the nano-vaccine can be used to treat brain metastases as well. Mouse models with late-stage melanoma brain metastases had already been established following excision of the primary melanoma lesion, mimicking the clinical setting. Research on image-guided surgery of primary melanoma using smart probes was published last year by Prof. Satchi-Fainaro’s lab.
“Our research opens the door to a completely new approach — the vaccine approach — for effective treatment of melanoma, even in the most advanced stages of the disease,” concludes Prof. Satchi-Fainaro. “We believe that our platform may also be suitable for other types of cancer and that our work is a solid foundation for the development of other cancer nano-vaccines.”
The Latest on: Melanoma
via Google News
The Latest on: Melanoma
- Metastatic Melanoma Drug Market Emerging Analysis, Future Growth And Business Opportunities 2026on January 9, 2020 at 11:08 pm
As the competition soars in the global Metastatic Melanoma Drug market, an increasing number of companies are looking exclusive insights into the prevailing trends in the market. Ameco Research study ...
- AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanomaon January 9, 2020 at 9:19 am
Cutaneous malignant melanoma (CMM) is the deadliest form of skin cancer and clinically challenging due to its propensity to develop therapy resistance. Reactive oxygen species (ROS) can induce DNA ...
- Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cellson January 9, 2020 at 2:30 am
The study population consists of 12 melanoma patients and 6 healthy donors (HDs) used as controls. Selected characteristics of all subjects are listed in STable 1. Age at blood draw did not differ ...
- Metastatic Uveal Melanoma Thereapeutics Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2027on January 8, 2020 at 5:19 pm
Ameco Research added new research report to its vast database titled "Global Metastatic Uveal Melanoma Thereapeutics Market 2019" which provides extensive and highly detailed information on the key ...
- Let's Talk About Melanomaon January 8, 2020 at 8:08 am
Whether you’ve just been diagnosed or worry you could have melanoma, you’re probably nervous, confused, and likely scared. We get it: Melanoma is a form of skin cancer that can be life-threatening.
- Melanoma Immunotherapy Enhanced by Targeting Treg Cell Control Proteinon January 8, 2020 at 5:19 am
For some people with advanced melanoma, such treatment has extended survival from months, to years. However, therapy is only effective in about 40% of people with advanced melanoma. Ze’ev Ronai, Ph.D.
- Melanoma can affect all ages: education, protection importanton January 7, 2020 at 8:35 am
Melanoma can affect anyone, even the young. Education and protection are critical, accordng to a Houston dermatologist.
- Study reveals a new approach to enhancing response to immunotherapy in melanomaon January 7, 2020 at 2:01 am
For some people with advanced melanoma, a deadly skin cancer, the treatment has extended survival to years instead of months. However, the treatment only works for about 40% of people with advanced ...
- A new strategy for boosting PD-1 blockers in melanomaon January 7, 2020 at 1:00 am
Immuno-oncology drugs like Bristol-Myers Squibb’s Opdivo and Merck’s Keytruda free up the immune system to attack cancer by blocking the checkpoint PD-1. But in melanoma, at least half of patients don ...
- Lower risk for malignant melanoma after bariatric surgeryon January 3, 2020 at 5:46 am
The surgery group included 23 individuals who developed malignant skin cancer, i.e. squamous cell carcinoma or malignant melanoma, in parallel with marked weight loss. The corresponding figure for ...
via Bing News